The demand for access to less invasive biopsy methods for cancer presents a critical decision for many provider laboratories.

In this webinar, Mr. Brady Davis MBA and Dr. Anna Lapuk, outline the pros and cons for bringing plasma testing in-house vs. send out services for oncology testing, suggest when organizations might find the transition most beneficial, and outline the process for transitioning from send out to in-house testing.

Critical factors for consideration such as staffing, oncologist and pathologist outreach and education, LIMS and data ecosystem integration, and clinical reporting will be presented.

 

Back

Recent Resources

Blog

August 30, 2022

CGC 2022 Key Takeaways

NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting